Abstract: The present invention relates to antibodies that bind to IgE and their use in the treatment of autoimmune diseases, particularly Bullous Pemphigoid (BP) and Chronic Spontaneous Urticaria (CSU). The anti-IgE antibodies comprise a variant Fc domain that binds to the Fc receptor FcRn with increased affinity relative to a wild-type Fc domain. The anti-IgE antibodies may comprise a variant Fc domain comprising the amino acids Y, T, E, K, F and Y at EU positions 252, 254, 256, 433, 434 and 436, respectively, wherein the variant Fc domain binds to human FcRn with increased affinity relative to a wild-type human IgG Fc domain.

Abstract: The present invention relates to antibodies that bind to IgE and their use in the treatment of autoimmune diseases, particularly Bullous Pemphigoid (BP) and Chronic Spontaneous Urticaria (CSU). The anti-IgE antibodies comprise a variant Fc domain that binds to the Fc receptor FcRn with increased affinity relative to a wild-type Fc domain. The anti-IgE antibodies may comprise a variant Fc domain comprising the amino acids Y, T, E, K, F and Y at EU positions 252, 254, 256, 433, 434 and 436, respectively, wherein the variant Fc domain binds to human FcRn with increased affinity relative to a wild-type human IgG Fc domain.

Abstract: A network model includes nodes, node property sets, authorization groups and authorization servers. The node property sets define how the nodes operate and authenticate. The nodes are member of the node property sets. The authorization groups are associated with the node property set. And, authorization servers are member of the authorization groups. In addition, a network model in a secure network environment has at least one community of interest. The network model includes at least one node being a member of a node property set that defines how the node operates and authenticates.

Abstract: The present disclosure is directed to edible organogel compositions that comprise an organogelator and a flavor component, and processes for preparing the organogel compositions. The organogel compositions may be included as the flavor component in confectionery products, such as chewing gums.

Abstract: A method of creating secure endpoints on a network includes registering by a node using a random selection algorithm to choose which server to register to; receiving by the node a property set ID of a property set that the node is a member of; and authorizing by the node using the property set ID to look up its authorization details in the property set. A method of creating secure endpoints on a secure network having at least one community of interest, includes registering by a node using a random selection algorithm to choose which server to register to; receiving by the node a property set ID of a property set that the node is a member of; and authorizing by the node through an authorization server using the property set ID to look up its authorization details in the property set; wherein the node and the authorization server are a member of the at least one community of interest.

Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).

Abstract: A DC disconnector comprising a static electrical contact, at least one moveable electrical contact comprising a plurality of conductor blades, and a shaft, coupled to the movable electrical contact. The shaft is configured to actuate the moveable electrical contact between a first configuration and a second configuration, wherein at least a portion of each conductor blade abuts the static electrical contact in the first configuration, and wherein the plurality of conductor blades are displaced from the static electrical contact in the second configuration.

Abstract: The present disclosure is directed to edible organogel compositions that comprise an organogelator and a flavor component, and processes for preparing the organogel compositions. The organogel compositions may be included as the flavor component in confectionery products, such as chewing gums.

Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).

Abstract: The present invention includes a composition and method of producing aspirin in situ, the method comprising: identifying a subject in need of aspirin or aspirin-like compounds; and providing the subject with a composition comprising: a source of methyl salicylate, an acetyl donor, and L-Arginine, wherein the composition is effective to produce aspirin-triggered resolvins in the subject without the deleterious effect of the aspirin or aspirin-like compounds in the stomach.

Abstract: The present disclosure is directed to edible organogel compositions that comprise an organogelator and a flavor component, and processes for preparing the organogel compositions. The organogelator is ethyl cellulose or a combination of ethyl cellulose and an edible wax, preferably candelilla wax, rice bran wax, carnauba wax, paraffin, beeswax, polyethylene wax or combinations thereof. The ethyl cellulose preferably has an average ethoxyl content of from 45.0% to 47.0% by weight of the ethyl cellulose or from 48.0% to 49.5% by weight of the ethyl cellulose. The organogel compositions may be included as the flavor component in confectionery products, such as chewing gums.

Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.

Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.

Abstract: The present invention relates to antibodies that bind to IgE and their use in the treatment of autoimmune diseases, particularly Bullous Pemphigoid (BP) and Chronic Spontaneous Urticaria (CSU). The anti-IgE antibodies comprise a variant Fc domain that binds to the Fc receptor FcRn with increased affinity relative to a wild-type Fc domain. The anti-IgE antibodies may comprise a variant Fc domain comprising the amino acids Y, T, E, K, F and Y at EU positions 252, 254, 256, 433, 434 and 436, respectively, wherein the variant Fc domain binds to human FcRn with increased affinity relative to a wild-type human IgG Fc domain.

Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.

Abstract: A network model includes nodes, node property sets, authorization groups and authorization servers. The node property sets define how the nodes operate and authenticate. The nodes are member of the node property sets. The authorization groups are associated with the node property set. And, authorization servers are member of the authorization groups. In addition, a network model in a secure network environment has at least one community of interest. The network model includes at least one node being a member of a node property set that defines how the node operates and authenticates.

Abstract: A method of creating secure endpoints on a network includes registering by a node using a random selection algorithm to choose which server to register to; receiving by the node a property set ID of a property set that the node is a member of; and authorizing by the node using the property set ID to look up its authorization details in the property set. A method of creating secure endpoints on a secure network having at least one community of interest, includes registering by a node using a random selection algorithm to choose which server to register to; receiving by the node a property set ID of a property set that the node is a member of; and authorizing by the node through an authorization server using the property set ID to look up its authorization details in the property set; wherein the node and the authorization server are a member of the at least one community of interest.

Abstract: A generic endpoint package includes a generic node configuration, which can be used by all nodes within a network, containing consolidated configuration information regardless of the operating system, the generic node configuration including: node property sets; common information containing rules to apply to nodes while in service mode and prior to authorization; and registration information directing the node to a pre-defined registration servers. A method of using a generic endpoint package includes deploying the generic endpoint package having a generic node configuration, which can be used by all nodes within a network, containing consolidated configuration information regardless of the operating system, the generic node configuration including: node property sets; common information containing rules to apply to nodes while in service mode and prior to authorization; and registration information directing the node to a pre-defined registration servers.

Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-? and uses thereof.

Abstract: Described, among other things, are dosage forms for administration to a subject, the dosage forms having at least six ingredients are selected are from the group consisting of clove powder, rutin, hesperidin, baicalin, sulforaphane, moringa leaf extract, rosmarinic acid, guava leaf extract, Panax notoginseng, EGCG, propolis, coriander extract, cardamom extract, cinnamaldehyde, chlorogenic acid, caper fruit, vescalagin, nutmeg extract, and naringenin. The dosage forms can serve as inhibitors of quorum sensing by infectious agents. The described combinations of selected natural products have the ability to inhibit quorum sensing. Quorum sensing is a means by which bacteria and viruses communicate with each other and induce virulence in the body. This combination of natural products is preferably included in nutraceutical formulations in order to promote human immune health.